4/3/2024 | PPPV | MannKind cuts debt by $48.1 million; repays loan, convertibles
|
4/26/2021 | BKPV | MannKind cuts debt by $49.5 million, restructures loans, notes
|
3/16/2021 | CV | MannKind greenshoe lifts 2.5% five-year convertibles to $230 million
|
3/2/2021 | CV | Market Commentary: Convertibles primary on fire; $3.23 billion in six deals on deck; Twitter below par
|
3/2/2021 | CV | Market Commentary: Morning Commentary: Convertibles primary on fire; $3.23 billion in six deals on deck
|
3/2/2021 | CV | New Issue: MannKind sells upsized $200 million five-year convertibles to yield 2.5%, up 30%
|
3/1/2021 | CV | Market Commentary: Primary markets $4.1 billion convertibles in eight deals; Twitter, Shake Shack eyed
|
3/1/2021 | CV | Market Commentary: Morning Commentary: Twitter, Shake Shack, MannKind convertible note offerings eyed
|
3/1/2021 | CV | MannKind talks $150 million five-year convertible notes to yield 2.25%-2.75%, up 37.5%-32.5%
|
12/1/2020 | BKPV | MannKind announces amendments to its credit facility with MidCap
|
8/7/2019 | BKPV | MannKind gets $75 million three-tranche term loan via MidCap Financial
|
6/11/2018 | CVLMPV | MannKind to issue stock in exchange for $6 million of convertibles
|
5/25/2018 | CVLM | MannKind to issue stock in exchange for $5 million 5.75% convertibles
|
3/12/2018 | DD | MannKind restructures, exchanges $86 million of debt
|
1/19/2018 | CVLM | MannKind says holders convert $5.59 million of 9.75% notes due 2019
|
10/23/2017 | CV | MannKind to defer $10 million on 9.75% notes, exchanges 5.75% notes
|
10/23/2017 | CVLM | MannKind to issue 5.75% convertibles due 2021 and stock in exchange
|
5/31/2016 | PP | U.S. PIPE issuance remains strong; Rodman & Renshaw takes award for top agent for year, month
|
5/10/2016 | PP | MannKind plans to conduct $50 million registered offering of its units
|
11/12/2015 | PP | MannKind sells $36.15 million of stock in registered direct offering
|
11/9/2015 | PP | MannKind to sell 50 million shares to investment funds in Israel
|
8/13/2015 | CVLM | MannKind to issue 5.75% subordinated convertibles due 2015 in exchange
|
7/29/2015 | CVLM | MannKind to issue new notes, stock for $84.6 million convertibles
|
9/29/2014 | HYIG | Market Commentary: South Jersey Industries places $110 million; MannKind secures $175 million promissory note
|
9/29/2014 | PV | New Issue: MannKind gets $175 million secured loan facility from Sanofi-Aventis unit
|
7/25/2014 | CV | Market Commentary: Morning Commentary: Tower Group convertibles get better bid; MannKind stock under pressure
|
6/27/2014 | PP | Market Commentary: Convertible primary market quiet after active week; MannKind gets Afrezza drug approval
|
6/27/2014 | CV | Market Commentary: Convertible primary market quiet after active week; MannKind gets Afrezza drug approval
|
4/7/2014 | CV | Market Commentary: Convertibles in line to slightly higher on hedge; Tesla, Priceline, Fluidigm in trade
|
4/7/2014 | CV | Market Commentary: Midday Commentary: Convertibles quiet as selling hits stocks; Genco steady just under par
|
4/2/2014 | CV | Market Commentary: New McDermott adds; DFC Global sister convertibles surge on buyout news; 51job deal on tap
|
3/28/2014 | CV | Market Commentary: Midday Commentary: MannKind quiet ahead of Afrezza regulatory decision; MGM flat to lower outright
|
3/28/2014 | CV | Market Commentary: Convertibles mostly quiet; HomeAway gains on swap from issue; hedged players lift SanDisk
|
3/21/2014 | CV | Market Commentary: Convertibles quiet; National Health lags dollar neutral; Navistar 'holds in;' Sterlite gains
|
11/5/2013 | CV | Market Commentary: Midday Commentary: Endo Health looks better on stock surge; Tesla active ahead of earnings news
|
11/5/2013 | CV | Market Commentary: Endo Health jumps on Paladin deal; General Cable, BroadSoft slide outright; deals emerge
|
11/4/2013 | BKPV | MannKind ups promissory note to $370 million, extends maturity to 2020
|
11/4/2013 | CV | Market Commentary: Covanta adds dollar neutral, shares higher; Volcano in line; Tesla active, slightly better
|
8/16/2013 | PPPV | MannKind to wrap $40 million tranche of $160 million convertibles sale
|
8/14/2013 | CV | Market Commentary: AMR extends dive after merger opposed; MannKind up on trial data; American Equity slips
|
7/1/2013 | PP | MannKind to sell $160 million convertibles through private placement
|
7/1/2013 | PV | MannKind to sell $160 million convertibles through private placement
|
2/11/2013 | CV | Market Commentary: New Molina upsizes; planned Molina, Starwood bid higher in gray; Regeneron 'comes in'
|
10/29/2012 | CV | Market Commentary: Convertibles silent: U.S. equity, bond markets shut as Sandy approaches; data delays eyed
|
10/19/2012 | PP | MannKind prices $103.6 million placement of units with the Mann Group
|
10/18/2012 | CV | Market Commentary: New Walter gains well on debut; Lam Research flat to 'in' slightly on hedge; MannKind down
|
10/17/2012 | PP | MannKind reports plans to price public offering of common-share units
|
8/31/2012 | CVIGPF | MannKind files $500 million shelf covering stock and debt securities
|
7/3/2012 | BK | MannKind amends terms of promissory note, extends borrowing period
|
5/9/2012 | BK | MannKind extends maturity date of $350 million note by three months
|
2/8/2012 | PP | MannKind concludes $86.25 million public offering of its equity units
|
2/3/2012 | CV | MannKind withdraws planned $161 million convertibles offering
|
2/3/2012 | CV | Market Commentary: Gilead adds on hedge on positive drug data; Tyson contracts on hedge; MannKind drops deal
|
2/3/2012 | PP | MannKind negotiates $75 million public offering of its equity units
|
2/2/2012 | CV | Market Commentary: Central European surges on Russian investment; Electronic Arts, Cemex add after earnings
|
2/1/2012 | CV | Market Commentary: BioMarin climbs outright, premium slips; Suntech Power surges; China Medical plunges
|
1/31/2012 | CV | MannKind to issue $161 million seven-year convertibles to yield 7%
|
1/31/2012 | CV | Market Commentary: RadioShack down on warning; MannKind plans new convertible, existing MannKind paper quiet
|
1/31/2012 | PP | MannKind could raise $50 million through public offering of its units
|
1/20/2012 | BK | MannKind extends maturity date of $350 million amended promissory note
|
11/28/2011 | HY | MannKind withdraws planned $370 million offering of six-year notes
|
11/28/2011 | HY | Market Commentary: AGCO prices; NCO Group, Landry's slate; MannKind out; Sears gains in firm market; funds lose
|
11/17/2011 | HY | Market Commentary: No pricings, but market awaits Kodiak, Entercom; new deals in narrow range; Jefferies jarred
|
10/27/2011 | HY | Market Commentary: Oasis, Acadia price deals; junk jumps on Europe debt news; funds see record huge inflows
|
10/18/2011 | HY | Market Commentary: Chesapeake unit hits road with deal; market mostly firmer; El Paso firms; builders better
|
10/12/2011 | HY | Market Commentary: Laredo drives by with add-on; Emdeon may price earlier; most names up solidly; Sprint strong
|
10/11/2011 | HY | Market Commentary: Junk jumps as trading resumes; Levi sizzles; Sprint fizzles; Kinetic Concepts downsizes deal
|
10/7/2011 | HY | Market Commentary: Clearwire bonds fall as Sprint looks to dump partner; Clear Channel gains momentum; ATP up
|
10/3/2011 | HY | Market Commentary: Junk market tailspin deepens as various issues slide multiple points; Kodak comes back
|
9/30/2011 | HY | Market Commentary: Newfield new issue falls with market; Default fears pressure ATP Oil bonds; Ally weak
|
9/26/2011 | HY | Correction: Global Hunter Securities is left bookrunner for Mannkind discount notes offering
|
9/23/2011 | HY | MannKind to start roadshow Monday for $370 million discount notes
|
9/23/2011 | HY | Market Commentary: Mannkind, Platinum deals slate as primary ends $1 billion week; secondary stays under pressure
|
9/23/2011 | HY | Market Commentary: Mannkind, Platinum deals slate as primary ends $1 billion week; secondary stays under pressure
|
5/27/2011 | CV | Market Commentary: Salesforce ends week slightly better; MannKind trades as shares creep up; Cubist mixed
|
1/24/2011 | CV | Market Commentary: Salesforce.com under pressure; RadioShack lower; Molycorp plans mandatory; Nielsen on tap
|
1/20/2011 | CV | Market Commentary: Ares Capital, Apollo mostly flat on debuts; Apollo remarketed at 98.5; MannKind plunges
|
8/31/2010 | CV | Market Commentary: Saks 'comes in' on hedge amid takeover talk; SanDisk gains, NetApp, Salesforce.com better
|
8/19/2010 | CV | New Issue: MannKind prices $100 million five-year convertibles at 5.75%, up 22.5%
|
8/19/2010 | CV | Market Commentary: SanDisk slightly higher in the gray; MannKind paper quiet on debut; Intel 2.95% bonds add
|
8/18/2010 | CV | Market Commentary: NetApp better; new GM convertible preferred paper eyed; SanDisk launches $1 billion deal
|
8/17/2010 | CV | Market Commentary: MannKind quiet in the gray, older MannKind 'marginally better'; Rubbermaid trades actively
|
8/16/2010 | CV | MannKind to price $100 million five-year convertible notes to yield 5.25%-5.75%, up 20%-25%
|
8/16/2010 | CV | Market Commentary: Convertibles muted; MannKind to price $100 million deal; King Pharma quiet as shares add
|
8/11/2010 | PP | New Issue: MannKind plans placements of stock with Seaside 88 and Mann Group
|
8/11/2010 | PP | Market Commentary: MannKind to raise funds, reduce debt; Green Mountain eyes $250 million; Silver Quest ups deal
|
4/30/2010 | CVIG | MannKind files $200 million shelf covering stock and debt securities
|
3/15/2010 | CV | Market Commentary: Amylin gains with stock; Knight prices upsized deal at the middle of talk; Group 1 to price
|
10/6/2009 | CV | Market Commentary: MannKind drops on partnership deal delay; Medtronic, Transocean gain; Avis, AirTran plan deals
|
10/2/2009 | CV | Market Commentary: UAL dips but ends higher on debut; Spansion recovers some; U.S. Steel, BorgWarner soften
|
9/22/2009 | CV | Market Commentary: AMR adds in gray, then upsizes; MannKind gains more: Goodrich, ATP, Incyte, Gaylord to price
|
9/21/2009 | CV | Market Commentary: AMR launches convertible; Amgen, MannKind, Nektar active in trade; Sonic, Kodak richen
|
2/27/2009 | BK | MannKind gets $350 million credit facility
|
10/3/2007 | PP | New Issue: MannKind to sell $250 million in stock
|
10/3/2007 | PP | Market Commentary: Enhanced Oil to raise C$25 million; MannKind to sell $250 million private placement of stock
|
10/2/2007 | BK | MannKind gets $350 million credit facility
|
8/9/2007 | CVIG | MannKind files $350 million shelf
|
6/11/2007 | CV | Market Commentary: MannKind takes off; Molson quiet in gray; Human Genome rebounds; three REITs, Trex launch deals
|
12/12/2006 | CV | MannKind greenshoe exercised, raising 3.75% convertibles to $115 million
|
12/7/2006 | CV | Market Commentary: Ford drives market into frenzy; MannKind leaps ahead; Superior Energy flat in gray; Prudential plans deal
|
12/7/2006 | CV | New Issue: MannKind prices $100 million seven-year convertibles richer than talk, at 3.75%, up 29%
|
12/6/2006 | CV | Market Commentary: Ford climbs further on upsize, new talk; First Potomac, Acadia flat on debuts; Superior Energy plans deal
|
11/28/2006 | CV | Market Commentary: Ventas flat on debut; AGCO higher in gray; MannKind quiet as stock borrow a concern
|
11/27/2006 | CV | MannKind to price $100 million seven-year convertibles, talked at 3.75%-4.25%, up 22%-28%
|
11/27/2006 | CV | Market Commentary: Ford stalls on financing plans; Scottish Re climbs on liquidity boost; Ventas gains in gray as deal reoffered
|
11/3/2006 | BT | MannKind still neutral by Merrill
|
11/3/2006 | BT | Jefferies keeps MannKind at hold
|
11/2/2006 | BT | MannKind losses since 1991 inception total more than $716 million
|
11/2/2006 | BTCV | Mannkind files $500 million shelf registration
|
10/26/2006 | BT | MannKind at neutral by Merrill
|
9/18/2006 | BT | MannKind cites positive results for Technosphere insulin
|
9/18/2006 | BT | Jefferies puts MannKind on hold
|
9/18/2006 | BT | MannKind at neutral by Merrill
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/14/2006 | BT | Merrill begins MannKind at neutral
|
9/14/2006 | BT | MannKind enrollment complete in phase 3 study of inhaled insulin
|
9/14/2006 | BT | MannKind on hold by Jefferies
|
8/3/2006 | BT | MannKind reports $54.8 million second quarter net loss, enters into $150 million loan agreement
|
8/3/2006 | BT | MannKind on hold by Jefferies
|
6/20/2006 | BT | MannKind says it is likely to run out of cash in third quarter, CEO offers $150 million loan
|
6/14/2006 | BT | Mannkind seeks partner for Technosphere insulin system
|
5/8/2006 | BT | Jefferies puts MannKind on hold
|
5/5/2006 | BT | MannKind considers collaboration to offset $600 million accumulated net loss
|
5/5/2006 | BT | MannKind 1Q operating expenses up, net loss rises to $0.87 per share
|
4/19/2006 | BT | MannKind: Study shows inhaled insulin has similar efficacy to injections in Type 1 diabetes patients
|
4/19/2006 | BT | Market Commentary: Genzyme crashes on miss; Nektar dips, ends higher; MannKind off; Icon better; Nabi adds another 4%
|
3/6/2006 | BT | MannKind begins two pivotal phase 3 studies of inhaled Technosphere Insulin
|
2/9/2006 | BT | MannKind gets key patents related to its cancer immunotherapy products
|
2/7/2006 | BT | Jefferies keeps MannKind at hold
|
1/23/2006 | BT | Market Commentary: Genitope shares fall nearly 10% on follow-on plans; Arena slides; SkyePharma up; MannKind drops
|
1/18/2006 | BT | Jefferies reiterates MannKind at hold
|
1/17/2006 | BT | MannKind says phase 2b studies of Technosphere inhaled insulin yield promising results
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
10/25/2005 | BT | Jefferies reiterates Mannkind's hold rating
|
10/13/2005 | BT | MannKind rated outperform by Leerink Swann
|
9/9/2005 | BT | MannKind price target upped by Jefferies
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
8/5/2005 | BTPP | New Issue: MannKind discloses details on $175 million private placement of stock
|
8/3/2005 | BT | MannKind price target upped by Jefferies
|
8/3/2005 | BT | Market Commentary: Lilly launches $1.5 billion floater; Human Genome $230 million convert at bat; MannKind taps PIPEs
|
8/3/2005 | PP | Market Commentary: PIPE volume back in full swing, sell-siders report; Central European Distribution raises $116.5 million
|
8/3/2005 | BTPP | MannKind raises $175 million in private placement of stock
|
7/29/2005 | BT | MannKind kept by Jefferies at underperform
|
6/15/2005 | BT | Mylan Labs upgraded by Lehman
|
3/11/2004 | CV | New Issue: MannKind raises $50 million from private placement convertible
|